Athira Pharma, Inc. (ATHA)

In the past six months, Athira Pharma reported its First Quarter 2025 financial results and presented data from its Phase 1 clinical trial of ATH-1105. The company announced its Second Quarter 2025 financial results and encouraging data from the Phase 1 clinical trial of ATH-1105. Athira Pharma announced a 10-for-1 reverse stock split. Athira Pharma reported its Third Quarter 2025 financial results, with an adjusted loss of -$1.68 per share, missing the consensus estimate.

As a clinical-stage biopharmaceutical company without commercialized products, Athira Pharma, Inc. has no established demand seasonality. The company's focus is on the development and clinical trials of its drug candidates.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, operating within the Health Technology sector and Biotechnology industry. The company modulates the neurotrophic Hepatocyte Growth Factor (HGF) system to activate neuroprotective pathways in the central nervous system. Its pipeline includes ATH-1105 for ALS and other neurodegenerative diseases, ATH-1020 designed to modulate the HGF system, Fosgonimeton (ATH-1017) for Alzheimer's and other dementias, and several new compounds in preclinical development.

Athira Pharma, Inc. is headquartered in Bothell, Washington, in the Seattle area of the United States. The company's research and development activities are primarily focused within the US.

Athira Pharma's brand reputation has been influenced by past research misconduct allegations involving its former CEO. In May 2024, Athira Pharma announced a proposed settlement of a stockholder derivative action, calling for corporate governance reforms and payment of attorney's fees. In 2025, the company paid a $4 million settlement related to allegations that the former CEO falsified research to secure a federal grant, highlighting past governance and research integrity concerns.

Athira Pharma, Inc. is owned by a mix of institutional shareholders, insiders, and retail investors. Institutional shareholders hold approximately 43.52% of the company, while Athira Pharma insiders own about 320.25%. Major institutional owners include Perceptive Advisors LLC, BML Capital Management, LLC, Vanguard Group Inc, Propel Bio Management, LLC, Simplify Asset Management Inc., Tang Capital Management Llc, Renaissance Technologies Llc, Acadian Asset Management Llc, Pathstone Holdings, LLC, and BlackRock, Inc. Significant individual and insider owners include Perceptive Advisors LLC, Joseph Edelman, Rtw Investments LP, Mark James Litton, Kevin Church, Glenna Mileson, and John M. Fluke Jr.